EQD2 and Overall Treatment Time in the High Dose Rate Brachytherapy of the Advanced Nasopharyngeal Carcinoma

Arunkumar Sharma


The aim of this study is to evaluate the decrease of EQD2 (biologically equivalent dose in 2 Gy fraction) and its correlation with local control of tumour in the treatment of the advanced nasopharyngeal carcinoma (NPC) when the overall treatment time is prolonged. A retrospective study was carried out on 43 advanced NPC (stage Ⅲ and Ⅳ) treated with fractionated High Dose Rate (HDR)–Brachytherapy boost, following external beam radiation therapy and chemotherapy in the period from 2009 to 2015. All patients were irradiated using a cobalt unit and a technique that employed two laterals, opposed fields with a dose of (66 ± 4) Gy. It was followed by HDR –Intra Luminal Radiotherapy after having a gap. The total EQD2 prescribed was (84.75 ± 7) Gy (range, 75–100.5 Gy). The probabilities of disease recurrence within a median follow-up of 24 months (range, 10–78 months) are expected as 0.12, 0.48 and 0.97 (P=0.05) for the overall treatment time of 75, 150 and 250 days respectively. The relative risk of local recurrence of Stage IV NPC patient is about 2.30 times higher than stage Ⅲ patients. The increase of total treatment time may be of different origin resulting in the fall of EQD2. It was observed that the recurrence of disease is significant (P < 0.05) when the overall treatment time is above 100 days where EQD2 lost becomes more than 0.10 Gy/day. The relative risk of disease recurrence of Stage Ⅳ is observed higher than stage Ⅲ nasopharyngeal patients.


HDR-brachytherapy, advanced NPC, EQD2, overall treatment time

Full Text:

PDF Citation


National cancer registry programme, North East population based cancer registries, incidence & distribution of cancer, 2nd report: 2005-2006, NCRP, Bangalore, India: Indian Council of Medical Research Sept, 2008.

Sharma AB, Singh TT, Singh KN, Gartia RK. Survey of patient dosimetry for head & neck cancer patients undergoing external radiotherapy: a study from NE hospitals of India. J cancer Res Ther 2009; 5(4): 263-266.

Chang JT, See LC, Tang SG, et al. The role of brachytherapy in early stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1996; 36: 1019-1024.

Largerwaard FJ, Levendag PC, Van Nimwegen A, et al. High precission boosting of the nasopharynx: Dosimetric comparison of conventional and conformal radiotherapy techniques. J HK Coll Radiol 2001; 4: 120-125.

Hunt MA, Zelefsky MJ, Wolden S, et al. Ttreatment planning and delivery of IMRT for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys 2001; 49: 623-632.

Marsiglia H, Haie-Meder C, Sasso G, et al. Brachytherapy for T1-T2 floor of the mouth cancers: The Gustave-Roussy Institute experience. Int J Radiat Oncol Biol Phys 2002; 52: 1257-1263.

Leborgne F, Leborgne JH, Zubizarreta E, et al. Cesium-137 needle brachytherapy boost after external beam irradiation for locally advanced carcinoma of the tongue and floor of the mouth. Brachytherapy 2002; 1: 126-130.

Malde R, Agarwal JP, Gupta T, Dinshaw K. High dose rate brachytherapy boost for primary nasopharyngeal carcinoma: preliminary results of an ongoing prospective study. Bull Cancer 2005; 92(7-8): 45-50.

Nag S, Dobelbower R, Glassgow G, Gustafson G, Syed N, Thomadsen B, Williamoon JF. Inter-society standards for the performance of brachytherapy: a joint report from ABS, ACMP and ACRO. Critical Reviews in Oncology/Hematology 2003; 48: 1-17.

Rafal T, Krzysztof S, Andrzej S, et al. Repopulation of tumour cells during radiotherapy is doubled during treatment gaps. Journal of Theoretical Medicine 2000; 2: 297-305.

Maciejewski B, Preuss-Bayer G & Trott KR. The influence of three numbers of fractions and of overall time on local control and late complications rate in squamous cell carcinoma of the larynx. Int J Radiat Oncol Biol Phys 1983; 9: 321-328.

Horiot JC, Bontemps P, Van den Bogaert W et al. Accelerated fractionation compared to conventional fractionation improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997; 44(2): 111-122.

Dishe S, Saunders M, Barret A, et al. A randomised multicentre trial of CHART vs conventional radiotherapy in head and neck cancer. Radiother Oncol 1997; 44(2): 123-136.

Dale RG. The application of linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985; 58: 515-528.

Ledorgne F, Fowler JF, Leborgne JF, et al. Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix. Radiat Oncol Investig 1997; 5: 289-299.

Stewart AJ, Jones B. Radiobiologic concepts for brachytherapy. In: Brachytherapy applications and techniques. Devlin PM(ed). Lippincott Williams &Wilkins, Philadelphia 2007.

Dimopoulos JCA. Dose volume histogram parameters and local tumour control in MRI guided cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys 2009; 75: 56-63.

Sharma AB, Singh TT, Singh JL, et al. Biological effective doses in the intracavitary high dose rate brachytherapy of cervical cancer. Journal of Contemporary Brachytherapy 2011; 3(4): 188-192.

Michael C Joiner. A simple α/β – independent method to derive fully isoeffective schedules following changes in dose per fraction. Int J Radiat Oncol Biol Phys 2004; 58: 871-875.

Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue response. Int J Radiat Oncol Biol Phys 1982; 8: 1981-1997.

Thames HD, Withers HR, Peters LJ et al. Changes in early and late radiation responses with altered dose fractionation: implications for dose survival relationships. Int J Radiat Oncol Biol Phys 1982; 8: 219-226.

Sood B, Garg M, Avadhani J et al. Predictive value of linear-quadratic model in the treatment of cervical cancer using HDR brachytherapy. Int J Radiat Oncol Biol Phys 2002; 54: 1377-1387.

Dala RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985; 58: 515-528.

Fowler J. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989; 62: 679-694.

Potter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and tems in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006; 78: 67-77.

Passi K, Kehwar TS, Vashistha R, et al. High dose rate brachytherapy with EBRT in the treatment of carcinoma of cervix: dosimetic and radiobiologic analysis. Journal of Radiotherapy in practice 2009; 8: 215-227.

Stanton PD, Cooke TG, Foster G, et al. Cell Kinetics in vivo of human breast cancer. Br J Surg 1996; 83(1): 98-102.

Keisch M, Vicini F, Kuske RR, et al. Initial clinical experience with the MammoSite breast brachytherapy application in woman with early-stage breast cancer treated with conserving therapy. Int J Radiat Oncol Biol Phys 2003; 55(2): 289-293.

Yongbok K,Werts ED, Trombetta MG, et al. Evaluation of the interfractional biological effective dose(BED) variation in MammoSite HDR brachytherapy. Journal of applied clinical medical physics 2010; 11(3): 124-134.

Al-Sarraf M, Pajak TF, Coopex JS, et al., Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma. A Radiation Therapy Oncology group study. J Clin Oncol 1990; 8: 1342-1351.

Cheng SH, Jian JJM, Tsai SY, et al. Long-term survival of nasopharyngeal carcinoma following concomital radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2000; 48: 1323-1330.

Levendag PC, Nijdam WM, Agthoven MV, et al. Chemotherapy and HDR brachytherapy in the management of advanced cancers of the nasopharynx: clinical impact of high technology – is it worth the cost. Brachytherapy 2002; 1: 11-20.

Peter CL, Wideke MN, Michel VA, et al. Chemotherapy and HDR brachytherapy in the management of advanced cancers of the nasopharynx: clinical impact of high technology – is it worth the cost? Brachytherapy 2002; 1: 11-20.

Jones B, Dale RG, Deehan C, et al. The role of biologically effective dose (BED) in clinical oncology. Clin Oncol (R Coll Radiol) 2001; 13: 71-81.

Jones B, Dale RG. The reduction of tumour control with increasing overall time: Mathematical considerations. Br J Radiol. 1996; 69: 830-838.

Tucker SL. Pitfalls in estimating the influence of overall treatment time on local tumour control. Acta Oncol. 1999; 38: 171-178.

Mandal A, Anupam KA, Lalit MA. Clinical significance of cumulative BED and overall treatment time in the treatment of carcinoma cervix. J Med Phys. 2007; 32(2): 68-72.

DOI: http://dx.doi.org/10.15383/jnpc.33


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

eISSN: 2312-0398

Asia Press is a professional Science, Technology and Medicine publisher, who owns rapid publication, Peer-Reviewed, Open Access Journals. Asia Press aims to promote “knowledge sharing”. As you know, the main barrier for free “knowledge sharing” is the cost of publishing and transfer. In order to encourage scholars and scientists to the max, and devote whole power to realize the aim of “knowledge sharing” and the benefit of “all” mankind, Asia Press performs a permanent policy of no charge for publication and access, and always open its door for authors worldwide.

© 2013-2017 by the Asia Press. All rights reserved.